---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-057398"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:21:39.175042+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Candel Therapeutics announces oral presentation of positive Phase 3 CAN-2409 data in prostate cancer at ASCO 2025

## Summary
- Phase 3 CAN-2409 data in localized prostate cancer accepted for oral presentation at ASCO 2025 (May 30-June 3, Chicago).
- Presenter is Theodore DeWeese, M.D., Dean and CEO of Johns Hopkins Medicine.
- Full abstracts released by ASCO on May 22, 2025 at 5:00 PM ET.
- Candel will post presentation details on its website after the event.

## SEC filing metadata
- accession: 0000950170-25-057398
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025057398/0000950170-25-057398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025057398/cadl-20250423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-057398
- JSON: https://secwatch.observer/filing/0000950170-25-057398.json
- Plain text: https://secwatch.observer/filing/0000950170-25-057398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.